| Zdroj: |
Waldenström, J, Färkkilä, M, Rembeck, K, Norkrans, G, Langeland, N, Mørch, K, Pedersen, C, Rauning Buhl, M, Nieminen, U, Nuutinen, H, Alsiö, Å, Holmström, L, Jungnelius, R, Lund, K, Rubensson, A, Torell, E, Westin, J & Lagging, M 2016, ' Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection : NORDynamIC trial and real-life experience ', Scandinavian Journal of Gastroenterology, vol. 51, no. 3, pp. 337-343 . https://doi.org/10.3109/00365521.2015.1087588 |
| Popis: |
OBJECTIVE: Interferon-free therapy for hepatitis C virus (HCV) infection is costly, and therefore patients with advanced fibrosis are prioritized. Although coupled with considerable side effects, a large proportion of genotype 2/3 infected patients achieve a sustained virological response (SVR) following interferon-based therapy. The present study evaluates experimental clinical trial and verifying real-life data with the aim of identifying patients with a high likelihood of favorable outcome following short interferon-based treatment.MATERIAL AND METHODS: The impact of established response predictors, e.g. age, ITPA and IL28B genetic variants, IP-10, liver histopathology and early viral kinetics on outcome was evaluated among HCV genotype 2/3 infected patients enrolled in the NORDynamIC trial. Similarly outcome was evaluated among Finnish and Swedish real-life genotype 2/3 infected patients treated for 12-16 weeks in accordance with national guidelines.RESULTS: In the NORDynamIC trial, age CONCLUSIONS: Short interferon-based therapy offers a high likelihood of achieving SVR for selected HCV genotype 2/3 infected patients, and is an acceptable option given that a thorough discussion of the side effects is provided prior to initiation. |
